Home › Essential Tremor › NCT04828798
Directional Versus Nondirectional DBS for ET
Directional Versus Nondirectional Deep Brain Stimulation of the VIM Thalamic Nucleus for Essential Tremor: Assessment of Therapeutic Window, Speech, Gait and Balance
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * A tremor syndrome of bilateral upper limb action tremor with at least 3 years' duration Exclusion Criteria: * Patients who have decided not to receive DBS for control of their medication-refractory essential tremor. * Patients with secondary tremor (ie not Essential Tremor), such as side effects from medications, secondary to another identified neurologic disease (eg multiple sclerosis, -----Parkinson's disease, dystonia). * Prior history of deep brain stimulation. * Prior history of thalamotomy. * A history or signs of dystonia, ataxia or parkinsonism. * Task specific tremor. * Orthostatic tremor. * Patients with cardiac pacemakers, defibrillators, or neurostimulators. * Patients who require MRI, ECT, rTMS, or diathermy. * Subjects with other type of neurological disease or injury.
About the study
This will be a single center (OHSU) proof of concept trial to demonstrate that directional deep brain stimulation (DBS) creates a larger therapeutic window for the treatment of essential tremor (ET), effectively treats ET, and minimizes effects on speech, gait and balance compared to nondirectional DBS.
What is being tested
- Deep brain stimulation of the VIM Thalamic nuclei (device)
Sponsor: Oregon Health and Science University · Participants: 24 · Started: Apr 1, 2021
Contact the study team
- Zoe Fanning · Phone: 503-494-7772
Official record on ClinicalTrials.gov — NCT04828798
Locations in the U.S.
| Oregon | Oregon Health & Science University, Portland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.